Inflation’s Toll: Some Serious Consequences, But Maybe a Silver Lining | Managed Healthcare Executive® State of the Industry Survey
Higher costs for employers and consumers, major layoffs, a decline in the quality of care are some consequences seen by respondents to the Managed Healthcare Executive® State of the Industry survey. Investment in technology that will improve efficiency might be a silver lining.
The recent news about inflation is that it may be easing just a little. However, prices in December 2022 were still 6.5% than they were in December 2021. Inflation and its consequences are the main economic concerns of the day.
Inflation’s effect on the healthcare sector tends to lag, partly because premiums and payment rates get locked in for periods of a year, sometime more. If the respondents to the Segal Health Plan Cost Trend Survey are correct, premiums for open-access preferred provider and point of service plans will increase by 7.4% this year, driven, in part, by double-digit increase in the cost of specialty drugs.
Respondents to the Managed Healthcare Executive® annual State of the Industry survey saw inflation as having several effects. Most (52%) indicated that they believe that costs will be passed on employers and consumers. A fairly large proportion (40%) said that major layoffs will occur, but one-third (33%) see a silver lining: Spending on technology will increase in an effort to increase efficiency. The same proportion — 30% — see operating margins decreasing and the quality of care suffering.
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
